Sign inJoin waitlistJoin the waitlist

HY

Habte Yimer

Physician · Mother Frances Hospital Regional Health Care Center

Credentials: · · · · ·

History

Mother Frances Hospital Regional Health Care Center
Present

Mayo Clinic
2001–2004
Internal Medicine
University of Illinois College of Medicine at Chicago
1998–2001
GONDAR COLL OF MED SCI, ADDIS ABABA UNIV, GONDAR, ETHIOPIA
1994–1998

Research

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
New England Journal of Medicine · 2019 · 567 citations
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
New England Journal of Medicine · 2023 · 435 citations
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
The Lancet Haematology · 2019 · 217 citations

JB
John Burke
8 papers
Mazyar Shadman
8 papers
AC
Aileen Cohen
7 papers
JS
Jeff Sharman
7 papers
JM
Jason Melear
5 papers
Jennifer Brown
5 papers
RR
Robert Rifkin
5 papers
SM
Sudhir Manda
5 papers
SO
Susan O'Brien
5 papers
Alessandra Ferrajoli
4 papers
Amanda Gillespie-Twardy
4 papers
IF
Ian Flinn
4 papers

Clinical trials

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
Site PI · Recruiting · Phase 1
ImmunityBio, Inc.
2025–2027
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Site PI · Recruiting · Phase 3
GlaxoSmithKline
2024–2031
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Site PI · Recruiting · Phase 2
Allogene Therapeutics
2024–2032
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Site PI · Unknown · Phase 1, Phase 2
Ascentage Pharma Group Inc.
2020–2025